Belite Bio Hits 52-Week High on $350M ADS Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 02 Dec 25
Source: Newsfilter
Belite Bio Inc's stock rose by 3.11%, reaching a 52-week high following the announcement of a $350 million ADS offering priced at $154 each.
The funds raised will support the company's commercialization efforts and expand its drug development pipeline, particularly for treatments targeting retinal diseases. This significant fundraising is expected to enhance Belite Bio's competitive position in the ophthalmic drug sector.
With strong underwriters like Morgan Stanley and BofA Securities backing the offering, market confidence in Belite Bio has been bolstered, paving the way for future growth and potential product launches.
Analyst Views on BLTE
Wall Street analysts forecast BLTE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLTE is 170.86 USD with a low forecast of 85.00 USD and a high forecast of 200.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 165.640
Low
85.00
Averages
170.86
High
200.00
Current: 165.640
Low
85.00
Averages
170.86
High
200.00
About BLTE
Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. The Company is focused on advancing novel therapeutics targeting retinal degenerative eye disease, such as Geographic Atrophy (GA), age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1), both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. Its lead product candidate, Tinlarebant, is an oral daily treatment for STGD1 and GA patients. In STGD1, it is developing Tinlarebant as a once-a-day tablet treatment to target Retinol binding protein 4 (RBP4) by disrupting vitamin A (retinol) binding to RBP4, which leads to reduced delivery of retinol to the eye and reduced accumulation of toxic vitamin A by-products. Its product candidate also includes LBS-009, an anti-RBP4 oral therapy targeting liver disease, including NAFLD, NASH, and T2D.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
